What Is Platelet-Rich Plasma?

Operative Techniques in Sports Medicine

Volumn 19, Issue 3, 2011, Pages 142-148

  Arnoczky, Steven P ^a   Delos, Demetris ^b,c   Rodeo, Scott A ^b,c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Fibrin; Leukocytes; Platelet rich plasma; Thrombin activation

Indexed keywords

CALCIUM CHLORIDE; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; THROMBIN;

ARTICLE; DENTAL SURGERY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE; FIBRIN FORMATION; HUMAN; IN VITRO STUDY; LEUKOCYTE; MONOCYTE; NEUTROPHIL COUNT; PRIORITY JOURNAL; SPORT INJURY; SPORTS MEDICINE; THROMBOCYTE RICH PLASMA;

EID: 80052318118     PISSN: 10601872     EISSN: 15579794     Source Type: Journal    
DOI: 10.1053/j.otsm.2010.12.001     Document Type: Article

References (62)

1. Foster T.E., Puskas B.L., Mandelbaum B.R., et al. Platelet-rich plasma: From basic science to clinical applications. Am J Sports Med 2009, 37:2259-2272.
2. Lopez-Vidriero E., Goulding K.A., Simon D.A., et al. The use of platelet-rich plasma in arthroscopy and sports medicine: Optimizing the healing environment. Arthroscopy 2010, 26:269-278.
3. Arnoczky S.P., Caballero O. Platelet-rich plasma to augment connective tissue healing: Making sense of it all. J Am Acad Orthop Surg 2010, 18:444-445.
4. Mei-Dan O., Mann G., Maffulli N. Platelet-rich plasma: Any substance to it?. Br J Sports Med 2010, 44:618-619.
5. Marx R.E. Platelet-rich plasma (PRP): What is PRP and what is not PRP?. Implants Dental 2001, 10:225-228.
6. Dohan Ehrenfest D.M., Rasmuson L., Albrektsson T. Classification of platelet concentrates: From pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin. LPRF). Trends Biotechnol 2009, 27:158-167.
7. Weibrich G., Kleis W.K., Hitzler W.E., et al. Comparison of the platelet concentrate collection system with the plasma-rich-in-growth-factors kit to produce platelet-rich plasms: A technical report. J Oral Maxillofac Implants 2005, 20:118-123.
8. Bird R.B., Stewart W., Lightfoot E.N. Transport Phenomena 2007, John Wiley and Sons, Hoboken, NJ. (ed 2).
9. Lucarelli E., Beretta R., Dozza B., et al. A recently developed bifacial platelet-rich fibrin matrix. Eur Cells Mater 2010, 20:13-23.
10. Visser L.C., Arnoczky S.P., Caballero O., et al. Platelet-rich fibrin constructs elute higher concentrations of TGF-β1 and increase tendon cell proliferation over time when compared to blood clots: A comparative in vitro analysis. Vet Surg 2010, 39:811-817.
11. Leitner G.C., Gruber R., Neumuller J., et al. Platelet content and growth factor release in platelet-rich plasma: A comparison of four different systems. Vox Sang 2006, 91:135-139.
12. Mazzucco L., Balbo V., Cattana E., et al. Not every PRP-gel is born equal: Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet®, RegenPRP-Kit®, Plateltex®, and one manual procedure. Vox Sang 2009, 97:110-118.
13. Castillo T.N., Pouliot M.A., Kim H.J., et al. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med 2011, 39:266-271.
14. Mishra A., Woodall J., Vieira A. Treatment of tendon and muscle using platelet-rich plasma. Clin Sports Med 2009, 28:113-125.
15. deVos R.J., Weir A., van Schie H., et al. Platelet-rich plasma injection for chronic Achilles tendinopathy: A randomized controlled trial. JAMA 2010, 303:144-149.
16. Blair P., Flaumenhaft R. Platelet α-granules: Basic biology and clinical correlates. Blood Rev 2009, 23:177-189.
17. Leslie M. Beyond clotting: The power of platelets. Science 2010, 328:562-564.
18. Mooren R., Hendriks E.J., van der Beuken J., et al. The effect of platelet-rich plasma in vitro on primary cells: Rat osteoblast-like cells and human endothelial cells. Tissue Eng 2010, 16:3159-3172.
19. Alberts B., Bray D., Lewis J., et al. Molecular Biology of the Cell 1994, Garland Publishing, New York, NY. (ed 3).
20. Ranly D.M., McMillan J., Keller T., et al. Platelet-derived growth factor inhibits demineralized bone matrix-induced intramuscular cartilage and bone formation. A study of immune-compromised mice. J Bone Joint Surg Am 2005, 87:2052-2064.
21. Han B., Woodell-May J., Ponticiello M., et al. The effect of thrombin activation of platelet-rich plasma on demineralized bone matrix osteochonductivity. J Bone Joint Surg Am 2009, 91:1459-1770.
22. Weibrich G., Hansen T., Kleis W., et al. Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. Bone 2004, 34:665-671.
23. Graziani F., Ivanovski S., Cei S., et al. The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. Clin Oral Implants Res 2006, 17:212-219.
24. de Mos M., van der Windt A.E., Jahr H., et al. Can platelet-rich plasma enhance tendon repair?. A cell culture study. Am J Sports Med 2008, 36:1171-1178.
25. Vavaken P., Saad F.A., Murray M.M. Age dependence of expression of growth factor receptors in porcine ACL fibroblasts. J Orthop Res 2010, 28:1107-1112.
26. Wiens L., Lutze G., Luley C., et al. Platelet count and platelet activation: Impact of a fat meal and day time. Platelets 2007, 18:171-173.
27. Weibrich G., Kleis W.K., Hafner G., et al. Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. J Craniomaxillofac Surg 2002, 30:97-102.
28. Mann K.G. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999, 82:165-174.
29. Clark R.A.F. The Molecular and Cellular Biology of Wound Repair 1996, Plenum Press, New York, NY. (ed 2).
30. Kakudo N., Minakata T., Mitsui T., et al. Proliferation-promoting effect of platelet-rich plasma on human adipose-derived stem cells and human dermal fibroblasts. Plast Reconstr Surg 2008, 122:1352-1360.
31. Alsousou J., Thompson M., Hulley P., et al. The biology ofplateket-rich plasma and its application in trauma and orthopaedic surgery. Bone Joint Surg 2009, 91B:987-996.
32. Bielecki T.M., Gazdzik T.S., Arendt J., et al. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances: An in vitro study. J Bone Joint Surg Br 2007, 89:417-420.
33. Moojen D.J., Everts P.A., Schure R.M., et al. Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J Orthop Res 2008, 26:404-410.
34. Everts P.A., Devilee R.J., Brown-Mahoney C., et al. Exogenous application of platelet-leukocyte gel during open subacromial decompression contributes to improved patient outcome. A prospective randomized double-blind study. Eur Surg Res 2008, 40:203-210.
35. Cieslik-Bielecka A., Bielecki T., Gazdzik T.S., et al. Autologous platelets and leukocytes can improve healing of infected high-energy soft tissue injury. Transfus Apher Sci 2009, 41:9-12.
36. Bielecki T., Gazdzik T.S., Szczepanski T. Benefit of percutaneous injection of autologous platelet-leukocyte-rich gel in patients with delayed union and nonunion. Eur Surg Res 2008, 40:289-296.
37. Tidball J.G. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 2005, 288:R345-R353.
38. McCarrel T., Fortier L. Temporal growth factor r3lease from platelet-rich plasma, trehalose lyophilized platelets, and bone marrow aspirate and their effect on tendon and ligament gene expression. J Orthop Res 2009, 27:1033-1042.
39. Muylle L., Joos M., Wouters E., et al. Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: Relationship between TNF alpha and IL-6 levels and febrile transfusion reactions. Transfusion 1993, 33:195-199.
40. Muylle L., Peetermans M.E. Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates. Vox Sang 1994, 66:14-17.
41. Muylle L., Wouters E., Peetermans M.E. Febrile reactions to platelet transfusion: The effect of increased interleukin 6 levels in concentrates prepared by the platelet-rich plasma method. Transfusion 1996, 36:886-890.
42. Stack G., Snyder E.L. Cytokine generation in stored platelet concentrates. Transfusion 1994, 34:20-25.
43. Aye M.T., Palmer D.S., Giulivi A., et al. Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage. Transfusion 1995, 35:117-124.
44. Palmer D.S., Aye M.T., Dumont L., et al. Prevention of cytokine accumulation in platelets obtained with the COBE spectra apheresis system. Vox Sang 1998, 75:115-123.
45. Martin P., Leibovich S.J. Inflammatory cells during wound healing: The good, the bad, and the ugly. Trends Cell Biol 2005, 15:599-607.
46. Toumi H., Best T.M. The inflammatory response: Friend or enemy for muscle injury?. Br J Sports Med 2003, 37:284-286.
47. Schneider B.S., Tiidus P.M. Neutrophil infiltration in exercise-injured muscle: How do we solve the controversy?. Sports Med 2007, 37:837-856.
48. Everts P.A., Hoffmann J., Weibrich G., et al. Differences in platelet growth factor release and leucocyte kinetics during autologous platelet gel formation. Transfus Med 2006, 16:363-368.
49. Giovanini A.F., Deliberador T.M., Gonzaga C.C., et al. Platelet-rich plasma diminishes calvarial bone repair associated with alterations in collagen matrix composition and elevated CD34+ cell prevalence. Bone 2010, 46:1597-1603.
50. Ortel T.L., Mercer M.C., Thames E.H., et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001, 233:88-96.
51. Sands J.J., Nudo S.A., Ashford R.G., et al. Antibodies to topical bovine thrombin correlate with access thrombosis. Am J Kidney Dis 2000, 35:796-801.
52. Lawson J.H. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 2006, 32(suppl 1):98-110.
53. Schoenecker J.G., Johnson R.K., Lesher A.P., et al. Exposure of mice to topical bovine thrombin induces systemic autoimmunity. Am J Pathol 2001, 159:1957-1969.
54. van Hinsbergh V.W., Collen A., Koolwijk P. Role of fibrin matrix in angiogenesis. Ann N Y Acad Sci 2001, 936:426-437.
55. Anitua E., Sanchez M., Nurden A.T., et al. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006, 24:227-234.
56. Fufa D., Shealy B., Jacobson M., et al. Activation of platelet-rich plasma using soluble type I collagen. J Oral Maxillofac Surg 2008, 66:684-690.
57. Harrison SL, Kevy S, Jacobson M, et al: Collagen activation of platelets provides a more sustained release of healing cytokines from platelets than thrombin: Transactions of the 56th Annual Meeting of the Orthopaedic Research Society, New Orleans, March 2010.
58. Dohan D.M., Choukroun J., Diss A., et al. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part I: Technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006, 101:37-44.
59. Dohan D.M., Choukroun J., Diss A., et al. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part II: Platelet-related biologic features. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006, 101:45-50.
60. Macri L., Silverstein D., Clark R.A. Growth factor binding to the pericellular matrix and its importance in tissue engineering. Adv Drig Deliv Rev 2007, 59:1366-1381.
61. O'Connor S.M., Impeduglia T., Hessler K., et al. Autologous platelet-rich fibrin matrix as cell therapy in the healing of chronic lower-extremity ulcers. Wound Repair Regen 2008, 16:749-756.
62. Sanchez M., Anitua E., Azofra J., et al. Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices. Am J Sports Med 2007, 35:245-251.